4,667 results match your criteria Tardive Dyskinesia


Possible involvement of apoptosis in the antipsychotics side effects: A minireview.

Clin Exp Pharmacol Physiol 2022 May 16. Epub 2022 May 16.

Biomedical Research Center, Slovak Academy of Sciences, Institute of Experimental Endocrinology, Dubravska cesta 9, Bratislava, Slovakia.

Antipsychotics are used in the treatment of schizophrenia and other psychiatric disorders. Generally they are divided into typical and atypical ones, according to the fact that atypical antipychotics induce less side effects and are more effective in terms of social and cognitive improvements. Their pharmacological effects are mediated via broad range of receptors that consequently influence different cellular signaling pathways. Read More

View Article and Full-Text PDF

Tardive dyskinesia in Chinese patients with schizophrenia: Prevalence, clinical correlates and relationship with cognitive impairment.

J Psychiatr Res 2022 Apr 25;151:181-187. Epub 2022 Apr 25.

CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; Department of Psychology, University of Chinese Academy of Sciences, Beijing, China. Electronic address:

Objective: Tardive dyskinesia (TD) has a high prevalence and is one of the distressing side effects of antipsychotic medications. Few studies have explored the relationship between TD, clinical correlates, and cognition. The aim of this study was to assess the prevalence, clinical correlates and cognitive impairment of co-occurring TD in Chinese patients with schizophrenia. Read More

View Article and Full-Text PDF

Movement Disorders and Mortality in Severely Mentally Ill Patients: The Curacao Extrapyramidal Syndromes Study XIV.

Schizophr Bull 2022 Apr 29. Epub 2022 Apr 29.

Research Department, Psychiatric Centre GGz Centraal, Amersfoort, The Netherlands.

Background And Hypothesis: There is a substantial gap in life expectancy between patients with severe mental illness (SMI) and the general population and it is important to understand which factors contribute to this difference. Research suggests an association between tardive dyskinesia (TD) and mortality; however, results are inconclusive. In addition, studies investigating associations between parkinsonism or akathisia and mortality are rare. Read More

View Article and Full-Text PDF

Therapeutic use of melatonin in schizophrenia-more than meets the eye!

Authors:
Ahmed Naguy

World J Psychiatry 2022 Mar 19;12(3):533-535. Epub 2022 Mar 19.

Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh 22094, Kuwait.

Adjunctive melatonin use in schizophrenia, as supported by a modicum of evidence, has multiple transcending chronobiotic actions, including fixing concurrent sleep problems to bona fide augmentative antipsychotic actions, mitigating the risk of tardive dyskinesias, curbing the drastic metabolic syndrome and ultimately providing neuroprotective actions. Its use is rather an art than science! Read More

View Article and Full-Text PDF

Dysfunctional monocytic toll-like receptor 4 signaling pathway and cognitive deficits in chronic schizophrenia patients with tardive dyskinesia.

Neurosci Lett 2022 04 22;777:136581. Epub 2022 Mar 22.

Peking University HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Beijing, PR China. Electronic address:

Background: Mounting evidence suggests that the innate immune system is disrupted in schizophrenia patients with tardive dyskinesia (TD); however, the role of the toll-like receptor 4 (TLR4) signaling pathway remains unclear.

Methods: In this study, we quantified the expression of the monocytic TLR4 signaling pathway using flow cytometry, before and after lipopolysaccharide (LPS) stimulation, in chronic schizophrenia patients with (n = 61) and without TD (NTD, n = 61) and healthy controls (HCs, n = 74). Psychopathological symptoms, the severity of TD, and cognitive function were assessed using the Positive and Negative Syndrome Scale (PANSS), Abnormal Involuntary Movement Scale (AIMS), and MATRICS Consensus Cognitive Battery (MCCB), respectively. Read More

View Article and Full-Text PDF

Correlation of Blood Biochemical Markers with Tardive Dyskinesia in Schizophrenic Patients.

Dis Markers 2022 8;2022:1767989. Epub 2022 Mar 8.

Department of Endocrine and Metabolic Diseases, Longhu Hospital, The First Affiliated Hospital of Shantou University Medical College, Shantou City 515041, China.

Objective: Oxidative stress factors and proinflammatory cytokines had been found to be involved in the pathogenesis of patients with tardive dyskinesia (TD). This study assumes that blood biochemical markers would have a link with TD in schizophrenia patients. To explore the correlation between blood biochemical markers and tardive dyskinesia in patients with schizophrenia (SCH). Read More

View Article and Full-Text PDF

Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.

Parkinsonism Relat Disord 2022 Apr 2;97:47-51. Epub 2022 Mar 2.

Teva Pharmaceuticals, West Chester, PA, USA.

Introduction: Deutetrabenazine is approved by the US Food and Drug Administration to treat tardive dyskinesia (TD) based on 2 pivotal, 12-week, placebo-controlled studies (ARM-TD and AIM-TD) evaluating safety and efficacy in patients with baseline total motor Abnormal Involuntary Movement Scale (AIMS) score ≥6. This analysis estimated the minimal clinically important change (MCIC) in total motor AIMS score in TD patients treated with deutetrabenazine.

Methods: The pooled analysis population included all patients in ARM-TD and AIM-TD who received study drug and had ≥1 postbaseline AIMS assessment. Read More

View Article and Full-Text PDF

Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.

Front Neurol 2022 23;13:773999. Epub 2022 Feb 23.

Georgetown University, Washington, DC, United States.

Background: Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved for the treatment of tardive dyskinesia (TD) in adults. In two 12-week pivotal studies, deutetrabenazine demonstrated statistically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores, with favorable safety/tolerability in TD patients. This study reports long-term efficacy and safety of deutetrabenazine in a 3-year, single-arm, open-label extension (OLE) study. Read More

View Article and Full-Text PDF
February 2022

: A Treasure of Functional Phytochemicals with Multimedicinal Applications.

Evid Based Complement Alternat Med 2022 28;2022:8288818. Epub 2022 Feb 28.

Department of Pharmacy, BGC Trust University Bangladesh, Chittagong 4381, Bangladesh.

is an ancient plant species that is thought to provide a variety of health benefits to living organisms and contains plenty of bioactive components, making it a chemically diversified plant. has been shown to have a variety of medicinal and pharmacological properties, including anticancer, antidementia, antidiabetic, antiobesity, antilipidemic, antimicrobial, antioxidant, antilipid peroxidation, antiplatelet, anti-inflammatory, hepatoprotective, antidepressant, antiaging, immunomodulatory, antihypertensive, and neuroprotective effects and is frequently used to treat neurological, cardiovascular, and respiratory diseases, such as tardive dyskinesia. Therefore, this review described the therapeutic applications of . Read More

View Article and Full-Text PDF
February 2022

Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder.

J Clin Psychopharmacol 2022 Mar-Apr 01;42(2):159-162

From the Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN.

Purpose: Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD.

Materials And Methods: Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Read More

View Article and Full-Text PDF

Clinical Phenotype of Tardive Dyskinesia in Bipolar Disorder.

J Clin Psychopharmacol 2022 Feb 25. Epub 2022 Feb 25.

From the Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN Lindner Center of HOPE/University of Cincinnati, Cincinnati, OH Department of Psychiatry and Behavioral Sciences, University of Minnesota, Minneapolis, MN Department of Psychiatry and Human Behavior, The University of Mississippi Medical Center, Jackson, MS Department of Psychiatry, Universidad Autónoma de Nuevo León, Monterrey, Mexico Department of Psychiatry, Facultad de Medicina, Universidad de los Andes Mental Health Service, Clínica Universidad de los Andes Center for Biomedical Research and Innovation, Facultad de Medicina, Universidad de los Andes, Santiago, Chile Department of Health Sciences Research, Mayo Clinic, Rochester, MN.

Purpose: Recognizing the negative impact that antipsychotic-induced movement disorders have on the quality of life and treatment outcomes in bipolar disorder (BD), this study aimed to assess clinical correlates and antipsychotic use patterns of tardive dyskinesia (TD+) in BD.

Materials And Methods: Participants with and without TD were included. Clinical variables were compared using t-test and χ2 test. Read More

View Article and Full-Text PDF
February 2022

[Tardive neuroleptic-induced dyskinesias].

Zh Nevrol Psikhiatr Im S S Korsakova 2022 ;122(1):31-35

Bekhterev National Medical Research Centerfor Psychiatry and Neurology, St. Petersburg, Russia.

Drugs that block dopaminergic transmission are currently widely used in the treatment of psychiatric diseases. One of the significant, common complications of therapy are tardive dyskinesias, which develop after prolonged, at least 3 months, therapy with antipsychotics and significantly reduce the quality of life of patients. Tardive dyskinesia is an extrapyramidal disorder, mainly manifested by involuntary hyperkinesis of the muscles of the face and tongue. Read More

View Article and Full-Text PDF
February 2022

Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Front Pharmacol 2021 24;12:834129. Epub 2022 Jan 24.

Pharmacogenetics Laboratory, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Tardive dyskinesia is a severe motor adverse event of antipsychotic medication, characterized by involuntary athetoid movements of the trunk, limbs, and/or orofacial areas. It affects two to ten patients under long-term administration of antipsychotics that do not subside for years even after the drug is stopped. Dopamine, serotonin, cannabinoid receptors, oxidative stress, plasticity factors, signaling cascades, as well as CYP isoenzymes and transporters have been associated with tardive dyskinesia (TD) occurrence in terms of genetic variability and metabolic capacity. Read More

View Article and Full-Text PDF
January 2022

Valbenazine for the Treatment of Adults with Tardive Dyskinesia.

Health Psychol Res 2021 18;9(1):24929. Epub 2021 Jun 18.

Department of Anesthesiology, Louisiana State University Health Shreveport.

Purpose Of Review: This a comprehensive review of the literature regarding the use of Valbenazine in treating tardive dyskinesia. A primarily oral movement disorder induced by chronic exposure to certain classes of medications, tardive dyskinesia is often resistant to many therapeutic approaches. This review presents the background, evidence, and indications for the use of Valbenazine as a treatment option for this condition. Read More

View Article and Full-Text PDF

Long-term effects of pallidal deep brain stimulation in tardive dystonia: a follow-up of 5-14 years.

J Neurol 2022 Jan 27. Epub 2022 Jan 27.

Movement Disorder and Neuromodulation Unit, Department of Neurology, Charité, University Medicine Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Germany.

Introduction: Pallidal DBS is an established treatment for severe isolated dystonia. However, its use in disabling and treatment-refractory tardive syndromes (TS) including tardive dyskinesia and tardive dystonia (TD) is less well investigated and long-term data remain sparse. This observational study evaluates long-term effects of deep brain stimulation (DBS) of the globus pallidus internus (GPi) in patients with medically refractory TS. Read More

View Article and Full-Text PDF
January 2022

Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials.

JAMA Psychiatry 2022 Mar;79(3):210-218

Department of Psychiatry, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.

Importance: Most evidence about efficacy and safety of antipsychotics in schizophrenia spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict eligibility criteria, RCTs represent only a part of the real-world population (ie, unselected patients seen in everyday clinical practice), which may result in an efficacy-effectiveness gap.

Objective: To quantify the proportion of real-world individuals with schizophrenia spectrum disorders who would be ineligible for participation in RCTs, and to explore whether clinical outcomes differ between eligible and ineligible individuals. Read More

View Article and Full-Text PDF

An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia.

Clin Psychopharmacol Neurosci 2022 Feb;20(1):154-166

Teva Pharmaceuticals, West Chester, PA, USA.

Objective: Antipsychotic medications may cause tardive dyskinesia (TD), an often-irreversible movement disorder characterized by involuntary movements that are typically stereotypic, choreiform, or dystonic and may impair quality of life. This study evaluated others' perceptions of abnormal TD movements in professional and social situations.

Methods: This was an experimental, randomized, blinded, digital survey in a general population sample. Read More

View Article and Full-Text PDF
February 2022

Metoclopramide induced acute dystonic reaction: A case report.

Ann Med Surg (Lond) 2022 Feb 11;74:103248. Epub 2022 Jan 11.

Department of Neurology, Mogadishu-Somali Turkish Training and Research Hospital, Somalia.

Introduction: and Importance: Metoclopramide is a frequently used anti-emetic medication for the treatment of vomiting secondary to medical conditions or chemotherapy. Metoclopramide is known to cause extrapyramidal symptoms (drug-induced movement disorder). While the dystonic reaction is an acute condition that may emerge after a single dose of metoclopramide, Tardive dyskinesia and Parkinsonism are generally seen after prolonged use. Read More

View Article and Full-Text PDF
February 2022

Comparison of Demographic and Clinical Features of Bipolar Disorder in Persons of African and European Ancestry.

J Racial Ethn Health Disparities 2022 Jan 21. Epub 2022 Jan 21.

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

Aim: This study quantified and compared demographic and clinical features of bipolar disorder (BD) in persons of African ancestry (AA) and European ancestry (EUR).

Methods: Participants enrolled in the Mayo Clinic Bipolar Biobank from 2009 to 2015. The structured clinical interview for DSM-IV was used to confirm the diagnosis of BD, and a questionnaire was developed to collect data on the clinical course of illness. Read More

View Article and Full-Text PDF
January 2022

Defining utility values for patients with tardive dyskinesia.

Curr Med Res Opin 2022 Mar 21;38(3):401-407. Epub 2022 Jan 21.

Teva Pharmaceuticals, Parsippany, NJ, USA.

Objective: To measure health state preferences and estimate utility values for tardive dyskinesia (TD) from the perspective of the US general population, accounting for factors affecting quality of life (QOL).

Methods: Participants from the general population were recruited and asked to watch and assess videos of professional actors simulating nine health states, including psychiatric disorders with/without TD and moderate-to-severe TD without any underlying disease. Time tradeoff (TTO) methods were used to elicit utility values, which ranged from -1 (worse than death) to +1 (perfect health) and represented individual preferences for avoiding specific health states associated with TD. Read More

View Article and Full-Text PDF

Vitamin E in the treatment of tardive dyskinesia: a meta-analysis.

Int Clin Psychopharmacol 2022 03;37(2):60-66

Department of Neurology, People's Hospital of Wuzhou, Wuzhou, Guangxi.

Long-term use of antipsychotic drugs is associated with tardive dyskinesia. At present, there is no satisfactory treatment for tardive dyskinesia. Some randomized trials suggested that vitamin E can improve tardive dyskinesia. Read More

View Article and Full-Text PDF

Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia.

J Psychopharmacol 2022 02 3;36(2):183-190. Epub 2022 Jan 3.

Research Division, Institute of Mental Health, Singapore.

Background: Both drug-induced Parkinsonism (DIP) and tardive dyskinesia (TD) have been shown to be associated with lower health-related quality of life (HRQOL) in schizophrenia, but few studies have examined their relative impact.

Aims: This study aimed to examine and compare the association of DIP and TD with HRQOL in schizophrenia.

Methods: In total, 903 patients with schizophrenia were assessed on the Positive and Negative Syndrome Scale (PANSS), Simpson-Angus Scale (SAS), and Abnormal Involuntary Movement Scale (AIMS). Read More

View Article and Full-Text PDF
February 2022

Double-Edged Sword: A Case with Withdrawal-Emergent Dyskinesia.

Turk Psikiyatri Derg 2021 ;32(4):283-285

Tardive dyskinesia is defined as involuntary athetoid or choreiform movements that develop due to the use of neuroleptic drugs for at least a few months. Tongue, lower face, jaw, upper and lower extremities are the most affected parts of the body in tardive dyskinesia. Quality of life is negatively affected because of the low remission rates. Read More

View Article and Full-Text PDF
December 2021

(+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia.

Front Pharmacol 2021 7;12:770377. Epub 2021 Dec 7.

School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, China.

Valbenazine and deutetrabenazine are the only two therapeutic drugs approved for tardive dyskinesia based on blocking the action of vesicular monoamine transporter 2 (VMAT2). But there exist demethylated inactive metabolism at the nine position for both them resulting in low availability, and CYP2D6 plays a major role in this metabolism resulting in the genetic polymorphism issue. 9-trifluoroethoxy-dihydrotetrabenazine (13e) was identified as a promising lead compound for treating tardive dyskinesia. Read More

View Article and Full-Text PDF
December 2021

A case of dose-dependent lithium-induced tardive dyskinesia.

Authors:
Mustafa Akkus

J Affect Disord 2022 02 4;299:205-206. Epub 2021 Dec 4.

Department of Psychiatry, University of Erzincan Binali Yıldırım, Mengucek Gazi Education and Research Hospital Erzincan, Turkey. Electronic address:

Tardive dyskinesia (TD) is a serious side effect that manifests itself mainly with choreiform and athetotic movement disorders, and generally occurs in the long term during antipsychotic treatments and is generally irreversible. We report a 67-year-old female patient having a diagnosis of Bipolar Disorder (BD) for 25 years, receiving 1200 mg/day lithium monotherapy for 10 years and in remission. The patient had been showing signs of TD-like syndrome for the last 6 months. Read More

View Article and Full-Text PDF
February 2022

Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones.

Mol Biol Rep 2022 Mar 1;49(3):1917-1923. Epub 2021 Dec 1.

Mestrado em Ciências da Saúde e da Vida, Universidade Franciscana (UFN), Santa Maria, RS, Brazil.

Background: Schizophrenia is a mental illness and its pharmacological treatment consists in the administration of antipsychotics like haloperidol. However, haloperidol often causes extrapyramidal motor disorders such as tardive dyskinesia (TD). So far, there is no effective treatment against TD and alternatives for it have been sought. Read More

View Article and Full-Text PDF

Characterizing the sensorimotor domain in schizophrenia spectrum disorders.

Eur Arch Psychiatry Clin Neurosci 2021 Nov 27. Epub 2021 Nov 27.

Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

The rapidly evolving field of sensorimotor neuroscience reflects the scientific and clinical relevance of sensorimotor abnormalities as an intrinsic component of the disease process, e.g., in patients with schizophrenia spectrum disorders (SSD). Read More

View Article and Full-Text PDF
November 2021

Restless tongue: Lingual Tardive Dyskinesia - A rare case report.

J Oral Biol Craniofac Res 2022 Jan-Feb;12(1):99-101. Epub 2021 Nov 3.

College of Dental Sciences & Research Centre, Bopal, Ahmedabad, India.

Tardive Dyskinesia is a movement disorder characterized by involuntary repetitive body movements, like chewing motions, cheek puffing, tongue protrusion and lip pursing. These symptoms appear during sleep and/or wakefulness. Report of involuntary movements of tongue is very rare, with a prevalence of only 15%-20%. Read More

View Article and Full-Text PDF
November 2021

Ketamine for psychotic depression: An overview of the glutamatergic system and ketamine's mechanisms associated with antidepressant and psychotomimetic effects.

Psychiatry Res 2021 12 9;306:114231. Epub 2021 Oct 9.

Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Mood Disorders Psychopharmacology Unit, Poul Hansen Family Centre for Depression, University Health Network, Toronto, ON, Canada; Brain and Cognition Discovery Foundation, Toronto, ON, Canada; Canadian Rapid Treatment Center of Excellence, Mississauga, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Electronic address:

Approximately 0.35-1% of the general population is afflicted with psychotic depression at some time in their life. Psychotic depression is a subtype of major depressive disorder characterized by mood congruent hallucinations and/or delusions. Read More

View Article and Full-Text PDF
December 2021